top of page
PAH patients who skip treatment don't do as well as patients who adhere to their treatment plan
In a study of data from the Pulmonary Hypertension Association Registry in the US, researchers looked at who was more likely to skip...
PHA Canada
Mar 31 min read
Â
Â
Newly diagnosed PAH patients on triple therapy have fewer hospitalizations vs. double therapy
A study looked at about 3000 pulmonary arterial hypertension patients and found that people who added selexipag to double therapy (an...
PHA Canada
Feb 181 min read
Â
Â
HYPERION sotatercept study has positive results, stops early
The HYPERION study examined whether adding sotatercept to other therapies for recently diagnosed patients with pulmonary arterial...
PHA Canada
Feb 101 min read
Â
Â
Â
Treprostinil benefits PAH patients with cardiovascular issues
Patients with pulmonary arterial hypertension (PAH) often also have cardiovascular issues such as diabetes or heart disease. A new...
PHA Canada
Feb 41 min read
Â
Â
Â
Sotatercept safe and effective across cardiac index groups
Cardiac index (CI) assesses the output of someone's heart based on their size. It measures heart function relative to the person's size...
PHA Canada
Dec 18, 20241 min read
Â
Â
Â
ZENITH study shows sotatercept is effective for PAH patients at high risk of mortality
The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or...
PHA Canada
Nov 26, 20241 min read
Â
Â
Â
Update: Canadian Drug Agency Funding Success for Pulmonary Hypertension Research
Great news for the Pulmonary Hypertension (PH) community! Through the Canadian Drug Agency's (CDA) funding initiative for rare diseases,...
PHA Canada
Oct 24, 20241 min read
Â
Â
Â
Rural and urban PH patients receive equivalent care
As most PH clinics are in large cities, PH patients living in rural or remote areas and who must travel long distances to their clinic...
PHA Canada
Oct 24, 20241 min read
Â
Â
Â
Sotatercept is now listed on Health Canada's website
We are pleased to announce that sotatercept, a new drug for patients diagnosed with pulmonary arterial hypertension (PAH), is now listed...
PHA Canada
May 13, 20241 min read
Â
Â
Â


Dr. Jason Weatherald Discusses the Burden of PAH on the PHaware Podcast
Tune in to the latest episode of the PHaware podcast, where Dr. Jason Weatherald, a pulmonologist at the University of Alberta, delves...
PHA Canada
May 5, 20241 min read
Â
Â
Â
The FDA has granted approval for the medication sotatercept
The US Food and Drug Administration (FDA) has granted approval for the medication sotatercept, a significant milestone in the treatment...
PHA Canada
Mar 26, 20241 min read
Â
Â
Â
The evolving landscape of pulmonary arterial hypertension clinical trials
In treatment trials for pulmonary arterial hypertension, looking at clinical events as outcomes instead of just 6-minute walk distance...
PHA Canada
Nov 26, 20221 min read
Â
Â
Â
Medications for the treatment of pulmonary arterial hypertension
PHA Canada's very own Dr. Sanjay Metha, Dr. Lisa Mielniczuk, and others have published a study in the European Respiratory Review. Read...
PHA Canada
Aug 10, 20221 min read
Â
Â
Â
Advances in Pulmonary Hypertension: Quality of Life
About Advances in Pulmonary Hypertension magazine: Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension...
PHA Canada
Jul 10, 20221 min read
Â
Â
Â
Social determinants of health in pulmonary arterial hypertension patients in the United States: Clinician perspective and health policy implications
Clinicians at 17 US pulmonary hypertension centres were interviewed about their understanding of social determinants of health in...
PHA Canada
Jul 8, 20221 min read
Â
Â
Â
Inhaled Seralutinib Shows Promise in 2 PAH Animal Models
This small study examined the use of social media by parents and caregivers of children with pulmonary hypertension. Seventy percent of...
PHA Canada
Jun 14, 20221 min read
Â
Â
Â
Opsyvni enters pCPA negotiations
In February, the panCanadian Pharmaceutical Alliance entered into formal pricing negotiations with the manufacturer of Opsyvni...
PHA Canada
Mar 28, 20221 min read
Â
Â
Â
Social Media Participation Among Parents and Caregivers of Children With Pulmonary Hypertension
This small study examined the use of social media by parents and caregivers of children with pulmonary hypertension. Seventy percent of...
PHA Canada
Mar 15, 20221 min read
Â
Â
Â
Palliative Care and Pulmonary Arterial Hypertension
In other diseases, palliative care is associated with better quality of life, symptom management, illness understanding, and reduced...
PHA Canada
Mar 15, 20221 min read
Â
Â
Â
BET Protein Inhibition for Pulmonary Arterial Hypertension
This pilot study added apabetalone to people's PAH therapy twice daily for 16 weeks to see if a future clinical trial evaluating...
PHA Canada
Mar 14, 20221 min read
Â
Â
Â
bottom of page
